DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06438874

WithdrawnPhase NA

Type 2 Diabetes Post Exercise Arterial Stiffness

Asset

GLP-1 / incretin class catch-all

Listed sites

0

Recruiting sites

—

Enrollment

—

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI 25-40•HbA1c 6.5-8%

Primary endpoint

•Arterial stiffness

Identifiers

Registered as

NCT IDNCT06438874
Org study IDSTUDY2024-0610

Timeline

Milestones

Study first posted2024-06-03actual
Last update posted2025-09-22actual
Study start2024-07estimated (month precision)
Primary completion2024-11estimated (month precision)
Study completion2024-12estimated (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age60 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

Individuals diagnosed with type 2 diabetes mellitus (T2DM).

•Age between 18 and 60 years old.
•Currently receiving treatment with a glucagon-like peptide 1 (GLP1) agonist for the management of T2DM for a minimum duration of six months.
•For control group no current use of a glucagon-like peptide 1 (GLP1) agonist for the management of type 2 diabetes mellitus (T2DM).
•HbA1c levels between 6.5-8%
•Body Mass Index (BMI) within the range of 25 to 40 kg/m2.

Exclusion criteria

•Coronary heart disease.
•Pulmonary disease (e.g. asthma, chronic obstructive pulmonary disease)
•Neurological disorders (e.g. Alzheimer's disease, dementia)
•Congestive heart failure.
•Peripheral vascular disease.
•Liver failure.
•Kidney failure.
•Alcohol abuse.
•Drug abuse.
•Smoking.
•Hypertension (defined as Systolic Blood Pressure ≥ 140 mmHg or Diastolic Blood Pressure ≥ 90 mmHg)
•Insulin therapy for the management of T2DM
•Severe obesity (defined as Body Mass Index >40 kg/m2);
•Pregnancy
•Non-English speaking individuals

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Cardiometabolic biomarkers

2 endpoints
Primary/protocol endpoint

Arterial stiffness

Time frame:Baseline and up to 20 minutes post exercise

change from baseline, improvement

Secondary/protocol endpoint

Blood pressure

Time frame:Through exercise test completion, an average of 10 minutes

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.